Clinical application and prospect of novel markers of rheumatoid arthritis
10.3760/cma.j.cn114452-20220413-00223
- VernacularTitle:类风湿关节炎新型标志物临床应用与展望
- Author:
Jiayi YUAN
1
;
Jin LI
;
Lieying FAN
Author Information
1. 同济大学附属东方医院检验科，上海200120
- Keywords:
Arthritis, rheumatoid;
Biomarkers;
Disease-modifying anti-rheumatic drugs;
Diagnosis;
Antibodies
- From:
Chinese Journal of Laboratory Medicine
2022;45(9):886-890
- CountryChina
- Language:Chinese
-
Abstract:
Rheumatoid arthritis (RA) is a chronic erosive arthritis. Early diagnosis, standardized treatment and regular monitoring of the disease will effectively mitigate disease progression and reduce the disability rate. Currently, traditional synthetic disease-modifying antirheumatic drugs (DMARDs) are used alone or in combination with new biological DMARDs or targeted synthetic DMARDS in the treatment of RA, resulting in effective remission in some refractory patients. However, the efficacy and toxicities of different treatments varies. With the development of proteomic and epigenetic technologies, some proteins, non-coding RNAs, and anti-drug antibodies (ADA) have been identified as potential markers for early diagnosis, concomitant diagnosis and disease assessment of RA. We summarized and analyzed the application prospects of novel RA diagnosis markers, including serum proteins, cell membrane proteins, non-coding RNAs, and ADA, with the aim of promoting the application of new markers that allow more precise diagnosis and treatment of RA.
